fashion -WSS

fashion

author：Wikipedia 2025-09-27 19:01:37 - browse：24561

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Vertex non

hotspot

WSS

Health Care Service Corp to buy Cigna Medicare Advantage plans

New clues to why women have higher risk of autoimmune disorders

Failure, not just success, should guide future doctors

Syphilis numbers in the United States reach record heights

White House pharmacy plagued with problems, investigation finds

Boston competes with Raleigh

knowledge

fashion

explore

Activists slam private health insurers over coverage restrictions

Biogen walks away from Aduhelm, years after polarizing approval

ChatGPT in medicine: STAT answers readers' burning questions

FTC sues over Novant Health acquisition of two N.C. hospitals

How to save PrEP access — and even expand it

Many breast cancer patients receive more radiation than needed

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Moonlake's readout produced a cash windfall. Risks remain

Zyn nicotine pouches become unlikely player in latest culture war

knowledge

Health Care Service Corp to buy Cigna Medicare Advantage plans

Paxlovid rebound happens. Why and to whom are still a mystery

'Brian's Song' at 50 still offers lessons about cancer for today

Syphilis numbers in the United States reach record heights

Medicare Advantage insurers face 0.2% cut to 2025 payments

With heat waves through August, officials warn of health risks

entertainment

hotspot

hotspot

Wikipedia